Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
about
Medical and surgical treatment for ocular myastheniaMedical and surgical treatment for ocular myastheniaMedical and surgical treatment for ocular myastheniaOcular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatmentClinical predictors for the prognosis of myasthenia gravis"Why do I always see double?" A misdiagnosed case of ocular myasthenia gravis for 10 years.Quality of life in purely ocular myasthenia in Japan.Ocular myasthenia gravis: a review.Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis.The anti-acetylcholine receptor antibody test in suspected ocular myasthenia gravis.Clinical and serological study of myasthenia gravis in HuBei Province, China.Fracture rate in patients with myasthenia gravis: the general practice research database.Neurological manifestations of Graves' disease: A case report and review of the literature.Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravisClinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.Safety of prednisone for ocular myasthenia gravis.Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityEFNS/ENS Guidelines for the treatment of ocular myasthenia.Glucocorticoids in myasthenia gravis - if, when, how, and how much?Blepharoptosis surgery in patients with myasthenia gravis.Frontalis sling procedure for ocular myasthenia gravis.Diagnosis of Tensilon-Negative Ocular Myasthenia Gravis By Daily SelfieThe effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.Overview of myasthenia gravis.Factors affecting outcome in ocular myasthenia gravis.Ocular presentation of myasthenia gravis: A natural history cohort.Prognostic factors and health-related quality of life in ocular Myasthenia Gravis (OMG).Progressive bilateral ophthalmoparesis--a case of simultaneous autoimmunity: balancing Graves' ophthalmoparesis and ocular myasthenia.Low conversion rate of ocular to generalized myasthenia gravis in Singapore.Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.Juvenile Myasthenia Gravis in Korea: Subgroup Analysis According to Sex and Onset Age.Ocular myasthenia gravis: controversies and updates.
P2860
Q24202289-D3DB4CF1-8E19-4D64-902F-2319659EB911Q24245255-3D98D602-1291-4437-AA2D-1F739CAF9971Q24246392-D86F20AA-D785-4370-9536-88F5332CD1E6Q24670367-82701A20-2B02-4B9C-82B2-4E1F975EF627Q33577194-85662499-8932-40C2-8D0A-03EF0AA4C422Q33625916-9EF0C79F-290B-4C09-9C05-54EA23DFA8BDQ33869796-0BD1A26D-A848-49D8-8746-F871C8AAC604Q34450858-ECC43E75-11D9-49DF-8F24-1A59DD463567Q34575021-EC3F1735-6D25-4CE7-9F63-B2A069166628Q34588412-165A250F-8EF0-4024-A861-46EF4EE7A3DEQ36143252-77524D1C-67A7-43EC-9548-4AE2A6A15145Q36568701-8DA5CF0F-6AB6-42DD-825D-CA250F753624Q36570587-8897F1B1-C479-4B0B-A800-5DA69AFA1BC7Q36694363-BAE00F90-9E2D-4391-BB35-C603E9D78F72Q37015471-8AA61F4F-BAB9-4A84-9718-6BE4FC6B7BFFQ37063766-B713A2B4-359E-4453-86EF-3914D4BA6675Q37252133-2119E802-5E87-4DA5-9507-DDF284307C65Q37315963-35E01E77-7518-4A9C-8F0D-328AB9A68DBAQ38182650-9D5AA051-25B0-4FD5-A4AA-178EC7DBF9E2Q38234725-95660241-BACC-4B45-80F3-C6BECE6BD0CBQ38321080-C66825E1-196C-495A-BE12-56DF9E116FCDQ41785399-D9741078-13C5-426A-BCBA-DFF7E063A7C1Q42364275-AC49571F-05B2-4326-BE5B-882648D7AF14Q44046461-0B72A401-96F6-4A91-83E9-F2782BDA126CQ44367084-CC7F4E00-B9EF-48DF-ABE2-2F5E59531AF1Q47690888-3438DE5A-4539-4CA4-8F76-775934850E6AQ48020624-B529D289-FB0B-48E2-9A57-2E751E0E4EFCQ48135299-07BE0B59-FC7E-4BAB-AA2E-0A45C02434CBQ49052263-05D335AD-6FEA-440C-A7FC-7C777BB7776BQ49582626-241DE57D-39DC-453F-8CFD-A0CE597E2918Q50954321-C94A7224-52A8-4043-9F68-1BE9D27B5B7BQ52657186-4095D0EA-40EC-4B16-BD98-F79F8FD7BC85Q53761765-E522C0FA-158A-49C4-A364-4F945E28CA8BQ54394549-6C76C18C-78D7-4205-91A4-3E5D710D7D27
P2860
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@en
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@nl
type
label
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@en
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@nl
prefLabel
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@en
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@nl
P2093
P1433
P1476
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
@en
P2093
Mark J Kupersmith
Peter Homel
Robert Latkany
P304
P356
10.1001/ARCHNEUR.60.2.243
P577
2003-02-01T00:00:00Z